Moderna has reported positive phase 3 clinical trial results for its seasonal influenza vaccine mRNA-1010, demonstrating a 26.6% relative vaccine efficacy over a licensed standard-dose vaccine in adults aged 50 and older. The vaccine showed strong efficacy against all included influenza strains, with a safety profile consistent with previous data. This milestone advances Moderna’s pursuit of a first mRNA-based flu vaccine approval in the U.S., potentially launching by the 2026-2027 flu season. The success also supports plans for a combination flu and COVID-19 vaccine submission.